Lunai Bioworks Inc. (LNAI): Nasdaq/NYSE listing notice — Lunai Bioworks receives Nasdaq notice for MVLS non-compliance; has 180 days to cure

Lunai Bioworks Inc.

MVLS fell below $35M for 30 consecutive business days; compliance deadline is April 27, 2026.
To cure, MVLS must close at $35M or more for a minimum of 10 consecutive business days.
No immediate effect on trading; stock continues on Nasdaq Capital Market under LNAI.
Failure to cure could lead to delisting notice; company may appeal to Nasdaq Hearings Panel.
Company plans to monitor MVLS and consider potential corporate actions to regain compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

Lunai Bioworks Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

October 27, 2025, Lunai Bioworks (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the $35 million minimum Market Value of Listed Securities (“MVLS”) requirement set forth in Nasdaq Listing Rule 5550(b)(2) for Capital Market. The Notice stated that the Company’s MVLS had been below $35 million for the previous 30 consecutive business days, and that, in accordance with Nasdaq rules, the Company has a period of 180 calendar days, or until April 27

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Lunai Bioworks Inc. filing history →

Source: SEC EDGAR

accession 0001731122-25-001446

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.